Patient Characteristics
| Characteristic | Data |
| Total patients (n) | 58 (100%) |
| Age at imaging (y) | |
| Mean | 67.7 |
| Median | 68 |
| IQR | 65–73 |
| Range | 48–80 |
| PSA at imaging (ng/mL) | |
| Mean | 18.1 |
| Median | 12.2 |
| IQR | 7.3–22.4 |
| Range | 1.2–81.6 |
| Gleason score (n) | |
| 7a | 11 (19.0%) |
| 7b | 25 (43.1%) |
| 8 | 4 (6.9%) |
| 9 | 18 (31.0%) |
| 10 | 0 |
| Pathologic T-stage (n) | |
| ≤pT2c | 26 (44.8%) |
| pT3a | 12 (20.7%) |
| ≥pT3b | 20 (34.5%) |
| Pathologic N-stage (n) | |
| pN0 | 40 (69%) |
| pN1 | 18 (31%) |
| Lymph nodes removed (n) | |
| Total | 1,137 |
| Median | 18 |
| IQR | 8 |
| Range | 8–53 |
| Lymph nodes with metastasis (n) | |
| Total | 71 |
| Median | 0 |
| IQR | 1 |
| Range | 0–15 |
| Injected activity (MBq) | |
| Mean | 327.7 |
| Median | 327 |
| IQR | 306.5–363 |
| Range | 132–410 |
| Uptake time (min) | |
| n | 82 |
| Median | 79.5 |
| IQR | 70–87.25 |
| Range | 60–153 |
IQR = interquartile range; PSA = prostate-specific antigen.